BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barón-esquivias G, Marín F, Sanmartín Fernandez M. Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice. Expert Review of Cardiovascular Therapy 2017;15:403-13. [DOI: 10.1080/14779072.2017.1309293] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Pimentel Quezada Y, Bonilla Palomas JL, Gámez López AL, Moreno Conde M, López Ibáñez MC, Gallego de la Sacristana López-Serrano Á. Has the clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban changed in the last 5 years of use? Future Cardiol 2018;14:47-53. [PMID: 29848089 DOI: 10.2217/fca-2018-0026] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Martí E, Segado A, Pastor-galán I, Amat P, Remigia MJ, Solano C, Navarro B. Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain. Future Cardiology 2018;14:3-8. [DOI: 10.2217/fca-2018-0020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fernández MS, Marín F, Rafols C, Arribas F, Barrios V, Cosín-Sales J, Sánchez MA; the EMIR Study Investigators:. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study). J Comp Eff Res 2021;10:583-93. [PMID: 33787316 DOI: 10.2217/cer-2020-0286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Escobar C, Martí-Almor J, Pérez Cabeza A, Martínez-Zapata MJ. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis. Rev Esp Cardiol (Engl Ed) 2019;72:305-16. [PMID: 29606361 DOI: 10.1016/j.rec.2018.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lobato SM, Tarrazo CT, Fernández EG, Alcalá MM. Clinical profile, adequacy of dosage and thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital of Asturias, Spain. Future Cardiology 2018;14:17-24. [DOI: 10.2217/fca-2018-0022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
6 Cerdá M, Cerezo-manchado JJ, Johansson E, Martínez F, Fernández M, Varela A, Rodríguez S, Bosch F, Santamaría A. Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population. Journal of Comparative Effectiveness Research 2019;8:165-78. [DOI: 10.2217/cer-2018-0134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
7 Escobar C, Martí-almor J, Pérez Cabeza A, Martínez-zapata MJ. Anticoagulantes orales directos frente a antagonistas de la vitamina K en pacientes con fibrilación auricular de la práctica clínica: revisión sistemática y metanálisis. Revista Española de Cardiología 2019;72:305-16. [DOI: 10.1016/j.recesp.2018.02.023] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 9.3] [Reference Citation Analysis]
8 Cerezo-manchado JJ, Navarro-almenzar B, Elvira-ruiz G, García-candel F, Flores-blanco PJ, Caro-martínez C, Manzano-fernández S, García-iniesta N, Sánchez-garcía J, Cabañas-perianes V, Moraleda-jiménez J. Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke. Future Cardiology 2018;14:31-7. [DOI: 10.2217/fca-2018-0024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]